You are here

Lyrica Meets Key Efficacy Endpoint in Pediatric Epilepsy Trial

Treatment reduces seizure frequency

Pfizer has announced positive results from a phase 3 study that evaluated the use of pregabalin (Lyrica) capsules CV and oral solution CV as adjunctive therapy for pediatric epilepsy patients 4 to 16 years of age with partial-onset seizures. Adjunctive treatment with pregabalin 10 mg/kg per day resulted in a statistically significant reduction in seizure frequency compared with placebo (the primary efficacy endpoint). Treatment with a lower pregabalin dosage (2.5 mg/kg per day) resulted in a numerical reduction in seizure frequency, which was not statistically significant.

The 12-week, double-blind, placebo-controlled, randomized, parallel-group study involved 295 pediatric subjects in 18 countries.

The safety profile observed in this study was consistent with that known for pregabalin in adults. The most common adverse events with pregabalin 10 mg/kg per day included somnolence, weight increase, increased appetite, and pyrexia. The most common adverse events associated with pregabalin 2.5 mg/kg per day included somnolence, upper respiratory tract infection, nasopharyngitis, and cough.

In the United States, pregabalin is indicated for the treatment of fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, and pain after shingles in adults. The medication is also indicated for the treatment of partial-onset seizures in adults with epilepsy who take one or more drugs for seizures. Pregabalin is not approved as adjunctive therapy for pediatric epilepsy patients with partial-onset seizures.

Sixty-five million people worldwide have epilepsy. One in 26 individuals in the U.S. will develop epilepsy at some point in life. Approximately three million people in the U.S. have epilepsy; approximately 10% of them, or 300,000, are pediatric patients. Partial-onset seizures are the most common seizure type.

Source: Pfizer; December 1, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs